JCEM :糖尿病患者HbA1c水平与心衰风险呈正相关

2013-12-10 佚名 丁香园

糖尿病是心力衰竭(HF)的一个独立危险因素。然而,糖尿病患者中,严格的血糖控制是否可以降低HF的发生尚不清楚。为了探讨糖尿病患者中不同HbA1c水平与HF风险的种族特异性关系,来自美国路易斯安那州立大学潘宁顿生物医学研究中心Gang Hu教授及其团队进行了一项研究,该研究发现非裔美国人和白种人糖尿病患者中,HbA1c与心力衰竭风险呈正相关。该研究结果在线发表在2013年12月2日的The Jour

糖尿病是心力衰竭(HF)的一个独立危险因素。然而,糖尿病患者中,严格的血糖控制是否可以降低HF的发生尚不清楚。为了探讨糖尿病患者中不同HbA1c水平与HF风险的种族特异性关系,来自美国路易斯安那州立大学潘宁顿生物医学研究中心Gang Hu教授及其团队进行了一项研究,该研究发现非裔美国人和白种人糖尿病患者中,HbA1c与心力衰竭风险呈正相关。该研究结果在线发表在2013年12月2日的The Journal of Clinical Endocrinology & Metabolism杂志上。【原文下载

该研究中,在路易斯安那州立大学(LSU)医院系统的17181例非裔美国人和12446例白人糖尿病患者中间,前瞻性研究基线不同HbA1c水平与平均6.5年随访期间期间发生HF风险的种族特异性关系。主要平均指标为2012年5月31日以前发生的HF.该研究结果表明,随访期间,5089例病例被确认发生HF.非裔美国人糖尿病患者基线不同HbA1c水平(<6.0%[对照组]、6.0-6.9%、7.0-7.9%、8.0-8.9%、9.0-9.9%和≥10.0%)相关的HF多元校正风险比(HRs)分别为1.00、1.02、1.21、1.29、1.37和1.49,而在白种人糖尿病患者中分别为1.00、1.09、1.09、1.43、1.49和1.61.在有和没有降血糖药物治疗的糖尿病患者中,以及不同年龄、性别、吸烟状态的糖尿病患者中,甚至在收缩性HF( ≤40%)和射血分数保留的HF(射血分数>40%)患者中,也存在这种级别的正相关。

该研究发现,非裔美国人和白种人糖尿病患者中,HbA1c与心力衰竭风险呈正相关。

研究背景:

糖尿病是心力衰竭(HF)的一种独立危险因素。当前美国心脏协会HF分级中将存在糖尿病定义为定义为心力衰竭A期(患者处在发生HF高风险)。多想观察性研究(但不是全部)提示糖尿病患者中,血糖控制程度与HF风险呈负相关。许多大型随机对照试验(RCTs)未能证实这个假说—糖尿病患者中严格血糖控制可以降低HF风险。我们的目的是非裔美国人和白种人糖尿病患者中,炎症基线和随访期间不同HbA1c水平与HF风险的种族特异性关系。

原文出处

Zhao W, Katzmarzyk PT, Horswell R, Wang Y, Johnson J, Hu G.HbA1c and Heart Failure Risk among Diabetic Patients.J Clin Endocrinol Metab. 2013 Dec 2. 【原文下载

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2062839, encodeId=c54b20628394a, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Sat Dec 14 10:03:00 CST 2013, time=2013-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994500, encodeId=ed931994500f9, content=<a href='/topic/show?id=84326326141' target=_blank style='color:#2F92EE;'>#正相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63261, encryptionId=84326326141, topicName=正相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Jun 07 08:03:00 CST 2014, time=2014-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777458, encodeId=12bc1e7745822, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Fri Apr 04 14:03:00 CST 2014, time=2014-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2015888, encodeId=1275201588826, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Wed Dec 18 14:03:00 CST 2013, time=2013-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389429, encodeId=ea15138942916, content=<a href='/topic/show?id=8425519625e' target=_blank style='color:#2F92EE;'>#心衰风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51962, encryptionId=8425519625e, topicName=心衰风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Thu Dec 12 02:03:00 CST 2013, time=2013-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473755, encodeId=f04614e375501, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Dec 12 02:03:00 CST 2013, time=2013-12-12, status=1, ipAttribution=)]
    2013-12-14 achengzhao
  2. [GetPortalCommentsPageByObjectIdResponse(id=2062839, encodeId=c54b20628394a, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Sat Dec 14 10:03:00 CST 2013, time=2013-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994500, encodeId=ed931994500f9, content=<a href='/topic/show?id=84326326141' target=_blank style='color:#2F92EE;'>#正相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63261, encryptionId=84326326141, topicName=正相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Jun 07 08:03:00 CST 2014, time=2014-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777458, encodeId=12bc1e7745822, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Fri Apr 04 14:03:00 CST 2014, time=2014-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2015888, encodeId=1275201588826, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Wed Dec 18 14:03:00 CST 2013, time=2013-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389429, encodeId=ea15138942916, content=<a href='/topic/show?id=8425519625e' target=_blank style='color:#2F92EE;'>#心衰风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51962, encryptionId=8425519625e, topicName=心衰风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Thu Dec 12 02:03:00 CST 2013, time=2013-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473755, encodeId=f04614e375501, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Dec 12 02:03:00 CST 2013, time=2013-12-12, status=1, ipAttribution=)]
    2014-06-07 zutt
  3. [GetPortalCommentsPageByObjectIdResponse(id=2062839, encodeId=c54b20628394a, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Sat Dec 14 10:03:00 CST 2013, time=2013-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994500, encodeId=ed931994500f9, content=<a href='/topic/show?id=84326326141' target=_blank style='color:#2F92EE;'>#正相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63261, encryptionId=84326326141, topicName=正相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Jun 07 08:03:00 CST 2014, time=2014-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777458, encodeId=12bc1e7745822, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Fri Apr 04 14:03:00 CST 2014, time=2014-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2015888, encodeId=1275201588826, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Wed Dec 18 14:03:00 CST 2013, time=2013-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389429, encodeId=ea15138942916, content=<a href='/topic/show?id=8425519625e' target=_blank style='color:#2F92EE;'>#心衰风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51962, encryptionId=8425519625e, topicName=心衰风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Thu Dec 12 02:03:00 CST 2013, time=2013-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473755, encodeId=f04614e375501, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Dec 12 02:03:00 CST 2013, time=2013-12-12, status=1, ipAttribution=)]
    2014-04-04 smallant2015
  4. [GetPortalCommentsPageByObjectIdResponse(id=2062839, encodeId=c54b20628394a, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Sat Dec 14 10:03:00 CST 2013, time=2013-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994500, encodeId=ed931994500f9, content=<a href='/topic/show?id=84326326141' target=_blank style='color:#2F92EE;'>#正相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63261, encryptionId=84326326141, topicName=正相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Jun 07 08:03:00 CST 2014, time=2014-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777458, encodeId=12bc1e7745822, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Fri Apr 04 14:03:00 CST 2014, time=2014-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2015888, encodeId=1275201588826, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Wed Dec 18 14:03:00 CST 2013, time=2013-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389429, encodeId=ea15138942916, content=<a href='/topic/show?id=8425519625e' target=_blank style='color:#2F92EE;'>#心衰风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51962, encryptionId=8425519625e, topicName=心衰风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Thu Dec 12 02:03:00 CST 2013, time=2013-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473755, encodeId=f04614e375501, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Dec 12 02:03:00 CST 2013, time=2013-12-12, status=1, ipAttribution=)]
    2013-12-18 Smile2680
  5. [GetPortalCommentsPageByObjectIdResponse(id=2062839, encodeId=c54b20628394a, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Sat Dec 14 10:03:00 CST 2013, time=2013-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994500, encodeId=ed931994500f9, content=<a href='/topic/show?id=84326326141' target=_blank style='color:#2F92EE;'>#正相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63261, encryptionId=84326326141, topicName=正相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Jun 07 08:03:00 CST 2014, time=2014-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777458, encodeId=12bc1e7745822, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Fri Apr 04 14:03:00 CST 2014, time=2014-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2015888, encodeId=1275201588826, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Wed Dec 18 14:03:00 CST 2013, time=2013-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389429, encodeId=ea15138942916, content=<a href='/topic/show?id=8425519625e' target=_blank style='color:#2F92EE;'>#心衰风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51962, encryptionId=8425519625e, topicName=心衰风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Thu Dec 12 02:03:00 CST 2013, time=2013-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473755, encodeId=f04614e375501, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Dec 12 02:03:00 CST 2013, time=2013-12-12, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2062839, encodeId=c54b20628394a, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Sat Dec 14 10:03:00 CST 2013, time=2013-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994500, encodeId=ed931994500f9, content=<a href='/topic/show?id=84326326141' target=_blank style='color:#2F92EE;'>#正相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63261, encryptionId=84326326141, topicName=正相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Jun 07 08:03:00 CST 2014, time=2014-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777458, encodeId=12bc1e7745822, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Fri Apr 04 14:03:00 CST 2014, time=2014-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2015888, encodeId=1275201588826, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Wed Dec 18 14:03:00 CST 2013, time=2013-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389429, encodeId=ea15138942916, content=<a href='/topic/show?id=8425519625e' target=_blank style='color:#2F92EE;'>#心衰风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51962, encryptionId=8425519625e, topicName=心衰风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Thu Dec 12 02:03:00 CST 2013, time=2013-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473755, encodeId=f04614e375501, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Dec 12 02:03:00 CST 2013, time=2013-12-12, status=1, ipAttribution=)]

相关资讯

杨文英:中国糖尿病流行病学变迁

图 我国中年段糖尿病患者率显著增高(1994年和2007年比较)我国糖尿病的患病特点 第五版的国际糖尿病联盟(IDF)版图显示,20~79岁的人群中,我国糖尿病患者9240万,位列全球第1位,占糖尿病总人数的1/4。我国糖尿病患病特点如下。 发病与经济水平呈正相关 1994年19省市大规模糖尿病调查结果显示经济水平和糖尿病发病率呈正相关。2007~2008年杨文英教授团队全国流

BMJ Open :中国高血压患者中糖尿病患病率高

为了探讨中国门诊高血压患者中糖尿病(DM)和使用空腹血糖(FPG)和餐后2小时血糖(2-hPG)新诊断DM的患病率,来自中国首都医科大学附属北京安贞医院的王薇教授及其团队进行了一项研究(Prevalence of diabetes mellitus in outpatients with essential hypertension in China: a cross-se

AHA 2013:EDTA螯合剂或降伴糖尿病心梗患者的心血管事件

于AHA 2013科学年会公布的美国一项研究表明,在年龄大于50岁且伴有糖尿病的心肌梗死后患者中,EDTA螯合剂治疗可显著减少心血管事件。但该研究并未充分证明对所有的伴糖尿病心梗后患者常规用螯合疗法。论文11月19日在线发表于《循环》(Circulation)。 【原文下载】 此项TACT研究以年龄≥50岁且既往伴有心肌梗死的患者为受试者,共633例糖尿病患者,被随机分为

CDS 2013:中国糖尿病研究获奖名单

日前,“2012年度中国糖尿病十大最具影响力研究奖”颁奖典礼在福州海峡国际会展中心隆重举行。李英睿、毕艳等医师或研究者获奖,中华医学会糖尿病学分会主任委员翁建平教授担任颁奖嘉宾,候任主任委员贾伟平教授主持颁奖典礼,副主任委员陆菊明、邹大进、周智广、朱大龙以及秘书长郭立新、许樟荣教授等参加了此次颁奖典礼。 2012中国糖尿病十大最具影响力研究获奖者名单(排名不分先后)

Lancet:全球糖尿病流行形势严峻

国际糖尿病联盟于11月14日–世界糖尿病日发布的“糖尿病地图”表明,由于糖尿病无情的传播,目前全球范围内估计有3亿8200万人受糖尿病影响,2035年这个数字有可能达到6亿人。这些受影响的人群中80%在发展中国家,而且,令人担忧的是,糖尿病发病年龄在下降。 结果是世界上8.3%人群普遍患有某种类型的糖尿病。糖尿病影响着社会经济的发展,由于合并症使临床治疗复杂化,增加医疗费用,而且可以使受

Diabetologia:MMP-10或参与糖尿病微血管并发症的发生

MMP-10与糖尿病肾病和视网膜病变的关系 金属蛋白酶-10(MMP-10)在1型糖尿病中的作用尚不清楚。为了探讨金属蛋白酶-10是否在糖尿病肾病和糖尿病视网膜病变发生和发展中发挥作用,来自西班牙纳瓦拉大学Nieves Díez教授及其团队进行了一项研究,该研究发现MMP-10参与1型糖尿病微血管并发症的发生。该研究结果发表在2013年12月的Diabetologia杂志上。